Objective Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that preferentially catalyzes the S-methylation of aromatic and heterocyclic sulfhydryl compounds, including Azathioprine (AZA). It has been reported that the level ofAZA toxicity is dependent on the TPMT genotypes in Caucasian individuals; we thus investigated this relationship in Japanese. Methods The TPMTgenotype was determined using peripheral blood cell DNAobtained from 36 Japanese patients with rheumatic diseases who were treated with AZA,by polymerase chain reaction (PCR) technique. Duration ofAZAadministration, white blood cell counts before and after AZAadministration, and side effects were investigated in each subject, and were compared between the patients with or without TPMTmutation. Results The TPMTallelotype was TPMT*1ITPMT*1 in 33 (91.7%) and TPMT*1/TPMT*3Cin 3 (8.3%) individuals.
Introduction
Azathioprine (AZA)is one of the most commonlyused immunosuppressants in the treatment of rheumatic diseases and other immune-associated systemic disorders. Somepatients suffer from severe bone marrowsuppression without allergic reaction after a short period ofAZAadministration, while most patients do not. Recently it was proposed that this variability in the sensitivity to AZAis largely due to the thiopurine Smethyltransferase (TPMT: EC2. 1.1.67) activity. TPMTis a cytosolic enzyme that preferentially catalyzes the S-methylation of aromatic and heterocyclic sulfhydryl compounds, including the anticancer agents mercaptopurine and thioguanine and the immunosuppressant AZA (1) . TPMTactivity shows codominant genetic polymorphism (2, 3) . To date 5 common alleles have been distinguished by the presence or absence of a single nucleotide substitution at 3 loci: TPMT*1 (wild type), TPMT*2 (G238C: G238^C at codon 80), TPMT*3A (G460A: G460->A at codon 154 and A719G: A719~^G at codon 240), TPMT*3B (G460A), and TPMT*3C (A719G) (4) (5) (6) .
By an in vitro yeast heterologous expression system, these mutations lead to a reduction in the TPMTprotein level as well as catalytic activity. In vivo, it was reported that 88.6% of healthy individuals show high TPMTactivity in erythrocytes, 1 1. 1% show intermediate activity, and 0.3% show TPMTdeficiency (2), representing wild homozygotes, heterozygotes, and mutant homozygotes, respectively (6). Black et al (7) reported that all patients heterozygous for mutant TPMTdiscontinued AZA therapy within one month, mainly due to leukopenia. Stolk et al (8) reported that gastrointestinal intolerance as a side effect ofAZAmight also be related to the reduced TPMTactivities.
To determine this relationship in Japanese, TPMTgenotypes in patients with rheumatic diseases treated with AZAwere investigated.
Materials and Methods
Patients and blood samples Peripheral blood samples were obtained from 36 Japanese patients with rheumatic diseases, including 15 of rheumatoid arthritis and 16 of systemic lupus erythematosus or Sjogren syndrome, who had been treated with AZAfrom 1996 to 1999. All patients were treated with 50 mg/day ofAZA. Blood was drawnfor clinical examination and the remaining portion was used for this study under informed consent.
DNApreparation and PCR GenomicDNAwas extracted from total blood cells using DNAExtractor WBKitá" (Wako, Osaka). One |il of DNAwas subjected to PCRamplification in a 50 |il reaction mixture containing 0.5 |liM of each primer, 0.2 mMof each deoxynucleotide, 10 mMTris-HCl (pH 8.5), 50 mMKC1, 1.5 mMMgCl2, 0.001% gelatin, and 2.5 units of Taq DNApolymerase (AmpliTaq Goldá", Perkin Elmer, Foster City, CA). The
PCRconditions were denaturation at 95°C for 1 minute, annealing at 58°C (G238C and A719G) or 55°C (G460A) for 1 minute, and extension at 72°C for 1.5 minutes for 35 cycles using a Program Temp Control System PC-800á" (ASTEC, Fukuoka). Specific primers were synthesized according to the previous reports (6, 9) as follows: G238C wild specific sense, Relationship between TPMTgenotype and AZAtoxicity Dose and duration of AZAadministration, white blood cell counts before and after AZAadministration, and side effects were investigated in each subject, and compared between the patients with or without TPMTmutation.
Results
Amongthe 72 alleles (36 individuals), frequency of the mutant allele for codons 238, 460, and 719 of the TPMTgem was 0 (0%), 0 (0%), and 3 (4.2%), respectively. Thus, the distribution of the TPMTgenotype was considered to be 91.7% of TPMT*1/TPMT*1 and 8.3% of TPMT*1/TPMT*3C.
Dose ofAZAadministered was 50 mg/day. Duration oi AZK administration was from 2 weeks (discontinued due to allergic reaction) to 106 weeks (median 36 weeks). Among them, ll cases discontinued AZAtreatment due to side effects: leucopenia (WBC<4,000/mm3 & <75% before administration) in 7 cases (Table 1 ) , abnormal liver function and/or gastrointestinal intolerance in 3 cases, and allergic reaction (fever elevation and eruptions) in 1 case.
All 3 patients (100%) with the mutant TPMTallele {TPMT*1/TPMT*3Q,two patients with Sjogren's syndrome under treatment with 5-6 mgof prednisolone and a patient with systemic lupus erythematosus under treatment with 7-20 mg of prednisolone, discontinued AZAtreatment due to leucopenia after 32, 106, or 40 weeks from commencement, respectively. On the other hand, only 4 patients (12%) without mutant TPMTalleles {TPMT*1/TPMT*1) showed leucopenia (p=0.0049, Fisher's exact test). However, since the patients with TPMTmutation developed leucopenia relatively late compared with those without TPMTmutation (Table 1) , it was not statistically significant when it was evaluated at 40 weeks from the commencementof AZAtreatment (p=0. 1 842, Fisher's exact test).
Discussion
We found 3 individuals (8.3%) with the TPMT*1/TPMT*3C genotype among 36 Japanese individuals and the others (91.7%) were considered to be the TPMT*1/TPMT*1 genotype. Although the total number analyzed in the present study is small and it was restricted to patients with rheumatic diseases, this distribution is different from Caucasians, in which TPMT*2or TPMT*3Aalleles are more common(p<0.01 , %2 test), but similar to African and Chinese populations (9, 10). All 3 patients with mutant TPMTallele discontinued AZA treatment due to leucopenia. However, in all 3 cases, bone marrowtoxicity developed after 32 weeksor morefrom commencement.In the previous reports in Caucasians, severe bone marrow toxicity and gastrointestinal intolerance developed more rapidly (7, 8) . Weconsidered two explanations for this discrepancy: First, the reduction in TPMTactivity level examined by in vitro yeast heterologous expression system was reportedly 100 fold in TPMT*2, >200 fold in TPMT*3A, nine fold in TPMT*3B, and about 30% in TPMT*3C (5, 1 1). Furthermore, TPMT*3Cprotein was revealed to have a degradation half-life comparable to the wild-type protein, while enhanced proteolysis of mutant TPMT proteins encoded by TPMT*2 and TPMT*3A alleles was observed, when heterologously expressed in yeast (12) . Thus, the reduction of the TPMTactivity in patients with TPMT*3C allele might not be so critical as in patients with TPMT*2or TPMT*3Aallele, which is more dominant in Caucasians. Second explanation maybe the relatively low dose of AZAadministration in Japan (commonly 1 mg/kg/day), compared to the dose commonlyprescribed for the treatment of rheumatoid arthritis in Caucasians (2-3 mg/kg/day). However, recently it was reported that erythrocytes obtained from patients with TPMT*3AfTPMT*3C genotype showed no TPMT function and patients with TPMT*1/TPMT*3C showed intermediate TPMTactivity, indicating that TPMT*3Callele is nonfunctional in vivo (6) , and when expressed in humans, TPMT*3Cis likely associated with lower TPMTprotein levels and catalytic activity in erythrocytes (13) . Considering these, the second explanation, that the relatively low dose of AZA administration in Japan is the reason for the mildness of side effects, is considered to be more plausible. Nevertheless, the fact that all 3 patients with TPMT*1/TPMT*3Cgenotype discontinued AZAtreatment due to leucopenia indicates that this AZAdosage, 50 mg/body/day, is still high for patients with a TPMTmutant allele. Moreover, since the leucopenia due to the reduced TPMTactivity is likely to occur relatively late with this dosage, we must continue close monitoring of hematologic parameters for patients with a mutant TPMTallele under low-dose AZAtreatment.
In conclusion, knowing the TPMTgenotype before commencement of AZAtreatment mayprovide useful information to determine the proper dosage for each patient, inducing the therapeutic efficacy as well as to decrease severe toxicity also in Japanese patients with rheumatic diseases.
